ZY Therapeutics

ZY Therapeutics is a clinical-stage biopharmaceutical company based in Research Triangle Park, North Carolina, specializing in the development of advanced drug delivery systems. The company utilizes its proprietary nanoparticle technology platform to reformulate established potent drugs, such as taxanes, to enhance their solubility, improve efficacy, and reduce systemic toxicity. Its lead candidate, ZY-010, is a nanoparticle formulation of docetaxel currently being evaluated in clinical trials for various solid tumors. By optimizing the pharmacokinetic profiles of proven therapeutic agents, ZY Therapeutics aims to provide safer and more effective treatment options for cancer patients. The company's pipeline also includes nanoparticle versions of cabazitaxel and paclitaxel, targeting a range of oncology indications.